Goldman Sachs
MDGL icon

Goldman Sachs’s Madrigal Pharmaceuticals MDGL Stock Holding History

Goldman Sachs’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,700
Closed -$3.3M – 6282
2024
Q4 		$3.3M Hold
10,700
– – ﹤0.01% 3857
2024
Q3 		$2.27M Hold
10,700
– – ﹤0.01% 4048
2024
Q2 		$3M Buy
10,700
+1,200
+13% +$286K ﹤0.01% 3615
2024
Q1 		$2.54M Hold
9,500
– – ﹤0.01% 3687
2023
Q4 		$2.2M Sell
9,500
-24,300
-72% -$4.25M ﹤0.01% 3846
2023
Q3 		$4.94M Buy
33,800
+23,800
+238% +$4.48M ﹤0.01% 2988
2023
Q2 		$2.31M Buy
+10,000
New +$2.71M ﹤0.01% 3757

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's MDGL Position: Q1 2026 in Review

Goldman Sachs reduced its Madrigal Pharmaceuticals (MDGL) stake by 9.3% in Q1 2026, selling an estimated $13.6M and leaving 277,371 shares worth $145M. The position accounts for 0.02% of the portfolio, ranked #837.

Goldman Sachs first reported a position in MDGL in Q2 2013 and has held it in 49 quarters since. The position peaked at $178M in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Goldman Sachs held 277,371 shares of Madrigal Pharmaceuticals worth $145M as of Q1 2026.
  • Goldman Sachs sold 28,476 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $13.6M.
  • Madrigal Pharmaceuticals made up 0.02% of Goldman Sachs's portfolio in Q1 2026, its #837 holding.
  • Goldman Sachs first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
  • Goldman Sachs's Madrigal Pharmaceuticals position peaked at $178M in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.